Combination medical products are hot and becoming hotter. In January, the Food and Drug Administration made headlines by quickly approving a fixed-dose-combination.
Once considered mainly an afterthought in a company's lifecyde-management strategy, controlled-release dosage forms are now positioned at the forefront of many formulation strategies.
An emerging family of biotech drugs promises to revolutionize the treatment of life-threatening diseases. "Antisense" drugs work at the molecular level by binding to messenger.
Costs of generic drugs are going up on the supply side, say chain drug pharmacy executives, as competition dries up and multisource products shrink to a single supplier or handful of suppliers.
BASKING RIDGE, N.J. -- Cardinal Health's recent purchase of an idle Schering-Plough plant in Raleigh, N.C., underscores the $40 billion wholesaler's growing presence in the drug-making process.
A few years ago, I took part in a congressional hearing on prescription-drug coverage for seniors. During the hearing, Robert Reischauer -- the former director of the Congressional Budget Office and now a budget expert at the Urban Institute
Product security and quality control were major themes of this year's Interphex trade show, held April 26-28 in New York City. A variety of interesting packaging machinery innovations were featured at the event.
Copyright 2010 Cannonbrew.com All rights reserved.
Unauthorized duplication in part or whole strictly prohibited by international copyright law.
